Most Read

Harbour BioMed is engaged in the discovery and development of therapeutics for oncology and immunological diseases. The financing round was led by GIC Private Limited, and participants included

The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory,

The company will invest a double-digit million-euro figure to add another 50 percent to its existing capacity. The new production lines will be installed at the company’s syringe

The global partnership, which will exclude the Greater China region, is expected to fetch more than $350m to Kelun-Biotech in addition to royalties based on annual net sales.

The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the U.S., Canada, Israel, and Turkey, and enroll approximately 260 patients. The Company

In their study in mice, the scientists discovered that liver injury triggered senescence, which is normally associated with aging or chronic disease. The researchers found that certain anti-cancer

Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and

Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to

Under the deal, the partnership will carry out research and development activities for the advancement of mRNA-based flu vaccines. BioNTech co-founder and CEO Dr Ugur Sahin said: “Today’s